Whole-genome optical mapping to elucidate myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions

Affiliations

¹ CHU Lille, Institute of Medical Genetics, France. Electronic address: benjamin.podvin@chru-lille.fr.
² CHU Lille, Institute of Medical Genetics, France.
³ CHU Lille, Laboratory of Hematology, France.
⁴ CHU Lille, Internal Medicine and Immunology, Centre de reference des maladies autoimmunes systémiques rares du Nord et Nord-Ouest de France (CeRAINO), France; U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France.
⁵ CH Arras, Hematology Department, France.
⁶ CH Arras, Laboratory of Hematology, France.
⁷ CHU Lille, Laboratory of Hematology, France; Univ. Lille, CNRS, Inserm, CHU Lille, IRCL, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.
⁸ CHU Lille, Institute of Medical Genetics, France; Univ. Lille, CNRS, Inserm, CHU Lille, IRCL, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.

Benjamin Podvin et al. Leuk Res. 2022 Dec.

. 2022 Dec:123:106972.

doi: 10.1016/j.leukres.2022.106972. Epub 2022 Oct 21.

¹ CHU Lille, Institute of Medical Genetics, France. Electronic address: benjamin.podvin@chru-lille.fr.
² CHU Lille, Institute of Medical Genetics, France.
³ CHU Lille, Laboratory of Hematology, France.
⁴ CHU Lille, Internal Medicine and Immunology, Centre de reference des maladies autoimmunes systémiques rares du Nord et Nord-Ouest de France (CeRAINO), France; U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France.
⁵ CH Arras, Hematology Department, France.
⁶ CH Arras, Laboratory of Hematology, France.
⁷ CHU Lille, Laboratory of Hematology, France; Univ. Lille, CNRS, Inserm, CHU Lille, IRCL, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.
⁸ CHU Lille, Institute of Medical Genetics, France; Univ. Lille, CNRS, Inserm, CHU Lille, IRCL, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.

No abstract available

Keywords: Hypereosinophilia; Karyotype; Optical Genome Mapping; PDGFRB.

Conflict of interest statement

Declaration of Competing Interest The authors declare no conflict of interest.

Feasibility of Optical Genome Mapping in Cytogenetic Diagnostics of Hematological Neoplasms: A New Way to Look at DNA.
Coccaro N, Anelli L, Zagaria A, Tarantini F, Cumbo C, Tota G, Minervini CF, Minervini A, Conserva MR, Redavid I, Parciante E, Macchia MG, Specchia G, Musto P, Albano F. Coccaro N, et al. Diagnostics (Basel). 2023 May 24;13(11):1841. doi: 10.3390/diagnostics13111841. Diagnostics (Basel). 2023. PMID: 37296693 Free PMC article. Review.
The Use of Optical Genome Mapping for the Detection of Tyrosine Kinase Gene Fusions in Myeloid/Lymphoid Neoplasms.
Vanhevel J, Rack K, Ameye G, Mokrani H, De Bie J, Michaux L, Dewaele B. Vanhevel J, et al. J Cell Mol Med. 2025 Jun;29(12):e70640. doi: 10.1111/jcmm.70640. J Cell Mol Med. 2025. PMID: 40533930 Free PMC article.
Hematological Neoplasms with Eosinophilia.
Morales-Camacho RM, Caballero-Velázquez T, Borrero JJ, Bernal R, Prats-Martín C. Morales-Camacho RM, et al. Cancers (Basel). 2024 Jan 12;16(2):337. doi: 10.3390/cancers16020337. Cancers (Basel). 2024. PMID: 38254826 Free PMC article. Review.